2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
47
Carcinoma, Hepatocellular
29
Neoplasms
18
Neoplasm Metastasis
14
Melanoma
14
Stomach Neoplasms
13
Esophageal Neoplasms
13
Colorectal Neoplasms
12
Nasopharyngeal Carcinoma
11
Esophageal Squamous Cell Carcinoma
10
Triple Negative Breast Neoplasms
9
Head and Neck Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Breast Neoplasms
8
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Lung Neoplasms
7
Carcinoma, Renal Cell
7
Biliary Tract Neoplasms
7
Small Cell Lung Carcinoma
6
Colonic Neoplasms
5
Cholangiocarcinoma
5
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Liver Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Interventions
Gemcitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
parathyroid hormone-related peptide (1-36)
2
niraparib
2
Ocoxin
2
Musculoskeletal Manipulations
2
Metformin
2
Clomiphene
2
Cisplatin
2
repotrectinib
1
relacorilant
1
pralsetinib
1
pembrolizumab
1
napabucasin
1
lutetium Lu 177 dotatate
1
fluorodopa F 18
1
copper dotatate CU-64
1
anlotinib
1
adrenosterone
1
Ultrasonography
1
Thalidomide
1
Sunitinib
1
Spironolactone
1
Parathyroid Hormone-Related Protein
1
Parathyroid Hormone
1
Paclitaxel
1
Octreotide
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endocrine System Diseases
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03492242
2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed
1,000 enrolled